Legal & General Group
AVBP icon

Legal & General Group’s ArriVent BioPharma AVBP Stock Holding History

Legal & General Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$339K Sell
14,676
-599
-4% -$13.5K ﹤0.01% 2451
2025
Q4 		$307K Buy
15,275
+485
+3% +$10.1K ﹤0.01% 2529
2025
Q3 		$273K Hold
14,790
– – ﹤0.01% 2566
2025
Q2 		$322K Buy
14,790
+1,197
+9% +$24.9K ﹤0.01% 2551
2025
Q1 		$251K Sell
13,593
-34
-0.2% -$832 ﹤0.01% 2578
2024
Q4 		$363K Buy
13,627
+10,783
+379% +$310K ﹤0.01% 2566
2024
Q3 		$66.8K Buy
2,844
+1,890
+198% +$42.9K ﹤0.01% 2763
2024
Q2 		$17.7K Buy
954
+58
+6% +$1.03K ﹤0.01% 3073
2024
Q1 		$16.1K Buy
+896
New +$18.1K ﹤0.01% 3054

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Legal & General Group's AVBP Position: Q1 2026 in Review

Legal & General Group reduced its ArriVent BioPharma (AVBP) stake by 3.9% in Q1 2026, selling an estimated $13.5K and leaving 14,676 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #2451.

Legal & General Group first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $363K in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Legal & General Group held 14,676 shares of ArriVent BioPharma worth $339K as of Q1 2026.
  • Legal & General Group sold 599 ArriVent BioPharma shares in Q1 2026, an estimated $13.5K.
  • ArriVent BioPharma made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2451 holding.
  • Legal & General Group first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Legal & General Group's ArriVent BioPharma position peaked at $363K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.